A multinational, multi-centre, randomised, double-blind, placebo-controlled, 3-way crossover study in migraine patients, treated with two doses of BGC20-1531 and placebo

Update Il y a 4 ans
Reference: EUCTR2009-010862-43

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

• To evaluate the effect of BGC20-1531 on headache response, defined as a decrease of headache from severe or moderate to mild or none at 2 hours post-dose without the use of rescue medication.


Inclusion criteria

  • acute migraine

Links